A growing body of evidence suggests that immune alterations, especially those related to inflammation, are associated with increased risk of schizophrenia and schizophrenia-related brain alterations. Much of this work has focused on the prenatal period, because infections during pregnancy have been repeatedly (albeit inconsistently) linked to risk of schizophrenia. Given that most infections do not cross the placenta, cytokines associated with inflammation (proinflammatory cytokines) have been targeted as potential mediators of the damaging effects of infection on the fetal brain in prenatal studies. Moreover, additional evidence from both human and animal studies suggests links between increased levels of proinflammatory cytokines, immune-related genes, and schizophrenia as well as brain alterations associated with the disorder. Additional support for the role of altered immune factors in the etiology of schizophrenia comes from neuroimaging studies, which have linked proinflammatory cytokine gene polymorphisms with some of the structural and functional abnormalities repeatedly found in schizophrenia. These findings are reviewed and discussed with a life course perspective, examining the contribution of inflammation from the fetal period to disorder presentation. Unexplored areas and future directions, such as the interplay between inflammation, genes, and individual-level environmental factors (e.g., stress, sleep, and nutrition), are also discussed.
S chizophrenia is a severe neurodevelopmental disorder resulting from genetic and environmental factors (1) . Although genetic factors contribute to the etiology of schizophrenia, an examination of environmental factors is needed to explain the 40%-55% discordance rate in monozygotic twins who do not share schizophrenia diagnoses (2) . Among the environmental contributors, infection and immune responses to infection have gained increasing attention as being integrally involved in the etiopathogenesis of the disorder (3) . A growing body of evidence links prenatal infection and maternal immune alterations during pregnancy to risk of schizophrenia and brain alterations found in the disorder (3) (4) (5) . Similarly, immune-related genes and immune alterations have been found in patients diagnosed with schizophrenia (6, 7) . This review will discuss the primary findings linking immune alterations, namely inflammation, to brain changes in schizophrenia. Because many of these findings stemmed from infection research, we will briefly summarize the role of infection in schizophrenia, focusing on the prenatal period. We will then discuss evidence linking immune alterations to risk of schizophrenia and to neurological alterations in the course of the disorder, with an emphasis on unexplored areas and future directions.
Overview of Link Between Schizophrenia and Infection
The first associations between schizophrenia and infection were found in ecologic studies (8) . Although findings have been mixed, winter to spring births (a period of heightened infections) and pregnancy during influenza epidemics have been associated with risk for schizophrenia among offspring (3) . However, ecologic studies are limited by their presumption of infection based on events that occur for an entire population without direct confirmation of exposure (3) .
Nevertheless, the association between schizophrenia and maternal infection was further supported by longitudinal cohort studies that prospectively collected obstetric information, including medical records and maternal sera from pregnancy, and identified offspring who developed schizophrenia spectrum disorders (3) . Although findings have not been completely consistent, a number of maternal infections during pregnancyincluding influenza (5, 9) , rubella (10), measles (11) , polio (12) , maternal upper respiratory infections (13) , genital and/or reproductive infections (14) , herpes simplex virus-type 2 (15) , and exposure to the protozoan parasite Toxoplasma gondii (16, 17) have been associated with risk of schizophrenia in offspring. Furthermore, maternal infections during pregnancy have been associated with schizophrenia-related neurocognitive/neuroanatomical abnormalities, including decreases in premorbid cognitive functioning (5, 10) , executive functioning problems after schizophrenia onset (18) , and increases in cavum septum pallucidum, a reliable marker of cerebral dysgenesis (19) .
One explanation for the associations between schizophrenia and many different infections that have not been consistently replicated is that these infections might impact the developing fetal brain through a common mechanism, such as the maternal immune response to infection (further discussed in Immune Response and the Fetal Brain section) (20) . In this regard, we would expect damage to the fetal brain to be linked to individual differences in maternal immune responses to infection and not necessarily to the infection itself. Some support for this idea comes from evidence suggesting that exposure to different strains of influenza during pregnancy differentially impacts the risk of schizophrenia in offspring, indicating that virulence of the infection might be key in conferring risk to the fetus (5) . Moreover, prenatal infection during pregnancy could interact with genetic liability for schizophrenia to increase risk among offspring. This hypothesis is supported by evidence that the influence of prenatal infection on increased risk of schizophrenia is increased when offspring have a family history of psychosis, although replication of this finding is needed (21) . Lastly, a number of individual factors that influence the immune system and susceptibility to infection could potentially contribute to these findings, such as maternal stress (22) , sleep (23) , exercise (24) , and other obstetric insults (25) , none of which have been explored in models examining maternal infection during pregnancy and risk of schizophrenia; therefore a number of questions remain for future research.
Immune Response and the Fetal Brain Cytokines
With the exception of parasitic infections, like toxoplasmosis gondii, most infections do not seem to cross the placenta; thus, damaging effects to the fetus are likely operating through maternal, fetal, and/or placental responses to infection (26, 27) . Among these responses to infections, prime candidates have been cytokines associated with inflammation (termed proinflammatory cytokines), some of which seem to cross the placenta (28, 29) . Cytokines are soluble polypeptide signaling proteins that are involved in initiation and maintenance of immune responses (30) and serve as critical mediators of the cross-talk between the brain and the immune system (31) . Infections activate proinflammatory cytokines (as well as other immune factors), such as tumor necrosis factor (TNF)-a, interleukin (IL)-1b, and IL-6 (32), which play crucial roles in the early defense against infection and the initiation and/or progression of inflammation (33) .
Relevant to prenatal studies in schizophrenia, pregnancy is characterized by a shift in immune functioning, favoring humoral immunity or T H 2 immune responses, with preferential production of T H 2 cytokines, such as IL-4, IL-5, and IL-10 (34). The relative increase in T H 2 cytokines during pregnancy has been associated with a downregulation of T H 1 proinflammatory cytokines, leading to a suppression of cell-mediated immunity and potentially decreasing the ability of the mother to respond to infections (35, 36) . In fact, disruption of the T H 1/T H 2 balance during pregnancy can lead to pregnancy failure (37, 38) , and influenza infection has been associated with increased rates of stillbirth and miscarriage, which might be consequences of elevations in proinflammatory cytokines (39) . These findings support the idea that pregnancy represents a period in which the mother is more vulnerable to infection and that elevations in proinflammatory cytokines represent an aberration from normal immune processes during pregnancy.
In humans, a number of pre-and perinatal conditions, many of which have been linked to increased risk of schizophrenia, such as infection, fetal hypoxia, maternal stress, and prepregnancy body mass index (BMI), have also been associated with increases in proinflammatory cytokines (4, 40) . Furthermore, fetal exposure to proinflammatory cytokines has been associated with white matter lesions in infant offspring (41) as well as neurodevelopmental abnormalities, such as periventricular leukomalacia, cerebral palsy, and mental retardation (42, 43) . Given that white matter abnormalities and premorbid motor and cognitive disturbances are frequently found in the course of schizophrenia, these results suggest that fetal exposure to inflammation can lead to neurodevelopmental sequelae related to schizophrenia even in the absence of a genetic vulnerability for schizophrenia (44) . Similarly, proinflammatory cytokines are implicated in neuronal death and dysfunction after injury or neurodegenerative disease in the adult brain, indicating that inflammation can alter neuronal processes at various stages of development even in individuals at presumed low genetic liability for schizophrenia (45) .
Schizophrenia and Proinflammatory Cytokines during Pregnancy
Given the aforementioned findings, it is not surprising that investigations have begun to examine maternal proinflammatory cytokines during pregnancy and schizophrenia risk in offspring. Specifically, studies have linked elevations in TNF-a levels at birth and elevations in IL-8 levels during the second and third trimesters with increased risk for schizophrenia in offspring (46, 47) . Despite these findings, it remains unclear whether there are specific cytokines and/or specific periods of gestation in which the fetal brain is particularly vulnerable to inflammation exposure.
Nevertheless, there is now evidence that increases in one maternal inflammatory cytokine during pregnancy are related to structural brain changes in schizophrenia. Ellman et al. (4) found a significant association between higher maternal IL-8 levels in the second/third trimesters of pregnancy and increases in ventricular cerebrospinal fluid (CSF) volume as well as volume reductions in the left entorhinal cortex, right posterior cingulate, and multiple basal ganglia structures in adults with schizophrenia, the latter of which approached significance (4). These findings are especially relevant to schizophrenia, because increases in ventricular volumes are the most well-replicated brain anomaly found in schizophrenia research (48) and the other neuroanatomical alterations have been found in schizophrenia and prodromal populations, suggesting that these brain abnormalities might have neurodevelopmental origins (48) (49) (50) . Interestingly, no brain alterations were observed among control participants after fetal exposure to increases in maternal IL-8, which is consistent with previous findings that liability for schizophrenia might be necessary for inflammation to damage the fetal brain (4). However, the control group was particularly small in the aforementioned study (n ¼ 8); therefore future studies are needed to determine whether brain alterations occur among those at presumed low liability for schizophrenia after fetal exposure to increases in maternal proinflammatory cytokines.
Animal Models of Immune Activation During Pregnancy
There has been a virtual explosion of studies examining maternal immune activation during pregnancy in animal models [for example, see (51) (52) (53) (54) (55) ], which is beyond the scope of this review. Consistent with the Ellman et al. study (4) , evidence suggests that fetal exposure to proinflammatory cytokines is associated with behavioral, cognitive, and neuroanatomical alterations consistent with schizophrenia, such as increases in ventricular volume and impairments in hippocampal-dependent tasks (26) .
An intriguing piece of these findings is evidence suggesting that prenatal exposure to infection or inflammation can lead to long-lasting immune abnormalities across development. Specifically, rodent models of prenatal influenza exposure (56, 57) , chronic gestational lipopolysaccharide (LPS) exposure (58) (59) (60) , prenatal IL-6 treatment in mid-to-late gestation (61) , and acute polyinosinic-polycytidylic acid treatment in early/middle gestation (62, 63) have identified immune abnormalities such as inflammatory changes in the peripheral and central nervous systems, enhanced microglia and/or astrocyte activation, and sustained increases in peripheral levels of proinflammatory cytokines among offspring. Similarly, exposure to prenatal infection can increase vulnerability for late-life alterations in cytokine production by inducing latent neuroinflammatory abnormalities that surface after exposure to environmental stressors throughout postnatal life (64) . Prenatal immune priming theories suggest that early inflammatory exposure during the pre-or perinatal period can lead to atypical and potentially more vigorous responses to subsequent environmental and/or immunological challenges (64) . These results suggest that fetal exposure to infection and maternal immune responses to infection might lead to alterations in immune functioning that continue to exert damaging effects on the brain well past the fetal period. This possibility has been virtually ignored in human samples but is supported by animal models that implicate cytokines like IL-6 as mediators of the long-term behavioral deficits found in offspring after maternal immune activation (65) and warrants considerable attention when attempting to understand the role of inflammation in the neurodevelopmental course of schizophrenia.
Immunological and Inflammatory Cytokine Alterations in Schizophrenia
Research on the influence of early life exposure to infection and inflammation on immune functioning across the lifespan is highly relevant, given repeated studies that have found immunological abnormalities in schizophrenia populations (66) . Furthermore, schizophrenia has been associated with inflammation and increased levels of cytokines, IL-2 receptors, IL-1 receptor agonists (IL-1RA), and acute phase reactants such as IL-1b and IL-6 in plasma (67, 68) . Potvin et al. (31) published a recent meta-analysis on inflammatory cytokine alterations in schizophrenia and found increased levels of in vivo peripheral IL-1RA, soluble IL-2R, and IL-6 in schizophrenia patients, suggesting evidence of immune activation in schizophrenia (31) . Importantly, increases in IL-6 and IL-1RA did not seem to be related to antipsychotic medication (31) . Findings on IL-1b levels in the CSF of patients with schizophrenia have been mixed, with this metaanalysis finding no significant effect sizes for IL-1b (31) , whereas a recent study of drug-naïve schizophrenia patients found significant elevations in IL-1b levels (69) . One plausible explanation for this discrepancy is that only 3 of the 62 studies included in the review by Potvin et al. (31) comprised drug-naïve patients. There is also some emerging evidence of increases in T H 2 cells (e.g., IL-4 producing lymphocytes) and T H 17 cells (presumed to be involved in inflammation and autoimmune disorders) among these cases (70) , although these types of cells have been studied significantly less than T H 1 responses.
Despite evidence of an inflammatory state persisting after disorder onset, it is unclear whether increases in inflammatory cytokines in schizophrenia populations represent alterations in immune functioning related to the causes of schizophrenia or inflammation in response to a variety of factors associated with the disorder, such as stress (71) , malnutrition (72) , and other disorder-related factors that are known to influence immune functioning (further discussed in the Interactions Between Immune and Individual Factors section). In fact, there is some evidence that individuals with schizophrenia have increases in prevalence of a variety of infections (e.g., HIV, hepatitis B and C) (73, 74) , which are known to lead to increases in inflammation. Furthermore, schizophrenia populations are less likely than nonpsychiatric populations to perform self-care or health promotion activities, which could put these patients at greater risk for a multitude of infections (75) . No studies have prospectively collected immune markers from the prenatal period until symptom onset; therefore the causal directionality of immune activation in schizophrenia populations remains unclear and presents a promising direction for future research.
Cytokines and Neuroanatomical Alterations: Neuroimaging Studies
A number of immune-related genetic polymorphisms have been associated with brain changes found in schizophrenia (Table 1) . Although findings have not always been consistent, genetic association studies (76) and neuroimaging studies (77) have linked genetic variability in the IL-1 gene complex to increased risk of schizophrenia and to some of the neuroanatomical alterations observed in schizophrenia patients (77) . The IL-1b and interleukin 1 receptor antagonist (IL-1RN) genes encode for IL-1b and IL-1RN, respectively, and are part of the IL-1 gene cluster on chromosome 2q13, which has been linked to schizophrenia (78) . The IL-1b and IL-1RN also are involved in neurodevelopmental processes (79) and acute and chronic neurodegeneration (80) , making them prime candidates for studies of their effect on brain morphology in schizophrenia.
Some of the most consistent magnetic resonance imaging (MRI) structural findings in schizophrenia, such as ventricular enlargement and temporal and frontal lobe volume reductions (81) , have been associated with polymorphisms of the IL-1 complex. Variability at the IL-1RN gene has been associated with ventricular enlargement in schizophrenia. Patients carrying allele n 2 of the IL-1RN gene-a genotype associated with enhanced IL-1b production and a more prolonged and severe pro-inflammatory immune response compared with other IL-1RN genotypes (82)-have been found to show significant enlargements of both left and right ventricles in MRI scans (77) . Similarly, among schizophrenia patients, allele n 2 carriers (genotype T/T or C/T) displayed bifrontal-temporal gray matter and generalized white matter tissue volume reductions (83) . Although these results suggest that the IL-1RN gene might contribute to the ventricular and gray matter volumetric changes observed in schizophrenia patients, an MRI study of first-episode nonaffective psychosis patients was unable to replicate these findings but found a nonsignificant trend toward larger ventricles at early phases of the disorder among carriers of allele n 2 (84) . Taken together, these findings suggest that IL-1RN gene variations might be involved in susceptibility to brain changes that occur over the course of the disorder in some individuals such that, compared with first-onset patients, chronic patients might show greater structural changes associated with IL-1RN n 2 (84). Polymorphisms of the IL-1 gene complex also have been associated with patterns of brain activity that are common in schizophrenia populations. Although there is inconsistency between studies, hypofrontality, or reduced activity of the dorsolateral prefrontal cortex, during a variety of cognitive tasks has been found in schizophrenia neuroimaging studies (85) (86) (87) . One positron emission tomography (PET) study found that a functional polymorphism (-511 C/T functional polymorphism) of the IL-1b gene was associated with decreased metabolic activity in the left dorsolateral prefrontal cortex of schizophrenia patients during an attention task, such that patients who were carriers of allele 2 (-511 T) (promotes greater expression of the gene that regulates IL-1b expression) showed lower metabolic activity relative to patients who were homozygous for allele 1 (88) . These findings provide some preliminary evidence that genetic polymorphisms in immune-related genes might contribute to both structural and functional brain abnormalities associated 
Genomic DNA extraction and genotyping of a biallelic baseexchange polymorphism at the promoter region (-511 C/T; rs16944) of IL-1b gene; fMRI imaging during the n-back working memory task 48 patients with chronic schizophrenia and 46 control subjects -511 C/T polymorphism of the IL-1b gene had differential effects in schizophrenia patients and control subjects such that schizophrenia patients carrying at least one copy of the T allele showed higher taskrelated prefrontal activation than CC homozygotes, whereas the IL-1b polymorphism did not modulate brain activation during task performance in control subjects
In patients, T-carriers showed higher activations than CC homozygotes, who in some cases showed deactivation rather than activation with schizophrenia. Nevertheless, it is unlikely that one polymorphism contributes to brain alterations in the preponderance of schizophrenia cases; therefore archiving immune-related genes associated with schizophrenia and using approaches examining multiple functionally related immune genes might reveal important future findings. Moreover, an unexamined possibility is that environmental (e.g., stress) and individual-level factors (e.g., medication-induced increases in BMI) that might be associated with both schizophrenia (89, 90) and increases in inflammatory cytokines (91,92) might additively or interactively influence the aforementioned findings. In this case, IL-1RN-associated increases in proinflammatory cytokines might not be evident until the disorder onset when disorder-related factors emerge.
Schizophrenia and Neuroinflammation
Neuroinflammation is characterized by activation of microglia cells, which are the resident macrophages of the brain and primary reservoirs of proinflammatory cytokines (93, 94) . Findings on neuroinflammation in schizophrenia have been mixed, with some postmortem studies finding increases in activated microglia cells in the brains of schizophrenia patients (95) (96) (97) , whereas others fail to find differences (98) (99) (100) (101) . Active neuroinflammation can be assessed with a PET tracer,
, which has been used to identify neuroinflammation in neurodegenerative diseases like Parkinson's disease, Alzheimer's disease, and multiple sclerosis (93). Doorduin et al. (93) found significantly higher binding potential of 11 C-(R)-PK11195 in the hippocampus of schizophrenia patients compared with healthy control subjects, indicating neuroinflammation in a focal area after the onset of psychosis. However, these studies are plagued by similar interpretation difficulties as previously noted, given that evidence of neuroinflammation after symptom onset could be the result of disorder-related factors. Evidence of neuroinflammation in the premorbid period of schizophrenia would ameliorate some of these potential confounds; however, such investigations have yet to be undertaken, would require large samples of individuals at risk for schizophrenia, and would be methodologically challenging (e.g., PET studies with younger populations).
Interactions Between Immune and Individual Factors
A number of genetic polymorphisms linked to immune functioning have been associated with risk for schizophrenia ( Table 2) . Specifically, among the available genome-wide association studies in schizophrenia research, polymorphisms associated with dysregulation in immune functioning-such as markers in the major histocompatibility complex region, a cluster of genes on human chromosome 6 that encode proteins involved in antigen processing (102)-have been consistently associated with schizophrenia (6, (103) (104) (105) . Polymorphisms in and around the IL-3 and IL-3 receptor a genes (106) (107) (108) and in the promoter region of the IL-10 gene (109), which code for the T H 2-produced anti-inflammatory cytokines IL-3 and IL-10, respectively, have also been linked to schizophrenia. Polymorphisms of the IL-10 gene have been associated with higher IL-10 production (110), and polymorphisms of the IL-3 gene have been associated with changes in IL-3 expression; however, it is unclear how the expression is altered, because there is a paucity of studies on the mechanisms of these polymorphisms. Similarly, polymorphisms in TNF-a (promoter region A2) and IL-1 gene complex (111) (112) (113) (114) . These polymorphisms typically lead to production of proinflammatory cytokines without any known infection (i.e., basal levels) as well as overproduction of proinflammatory cytokines in response to infection and might contribute to the observed elevations in proinflammatory cytokines found in schizophrenia populations (115) . Given these findings, it is possible that in prenatal studies of infection, if the fetus and/or the mother is a carrier of genetic polymorphisms associated with inflammation or dysregulation in immune functioning, then the fetus could be more vulnerable to the damaging influences of exposure to maternal infection (44) . Despite this possibility, no human study has directly examined the additive and/or interactive influences of specific risk alleles with maternal infection during pregnancy and/or other immune-related conditions during pregnancy, which is a promising area for future research with cohorts with archived prenatal sera. It also is possible that carriers of immune-related polymorphisms have lifelong exposure to increased levels of proinflammatory cytokines, thereby leading to potential damage to the brain across development. Again, this possibility has yet to be tested but seems promising given evidence from postmortem brain studies of increased expression of immune-related genes (e.g., IFITM2, IFITM3, SERPINA3) in the prefrontal cortex of schizophrenia patients (116, 117) and represents an intriguing area for future studies.
As mentioned previously, individual characteristics could contribute to alterations in immune functioning in pregnant and nonpregnant populations. For instance, factors such as increases in BMI (118), race (particularly African-American) (119), exercise (24), stress (22) , depression (120), sleep (23), nutrition (121) , and health-risk behaviors (e.g., substance use and abuse) (122) have been linked to altered immune functioning, susceptibility to infection, and schizophrenia. There is some support for these individual-level factors influencing cytokine levels among schizophrenia patients. One study found that increases in proinflammatory cytokines and chemokines were related to individual characteristics commonly found in schizophrenia populations (123) . Specifically, gender, increased BMI, hyperglycemia, diabetes, reduced high-density lipoprotein cholesterol or increased levels of triglycerides or the metabolic syndrome were associated with increases in a number of proinflammatory cytokines (e.g., TNF-a, IL-1B, IL-6) and chemokines, whereas only IL-1b and IL-6 were increased in the serum of patients not affected by any of the aforementioned characteristics (123) . Given these findings, a necessary step in determining how inflammation operates within the etiology of schizophrenia is to examine the interactions between inflammation and other individual-level factors, including lifestyle and environmental variables as well as variations in related genetic factors.
Remarks
Most studies on inflammation and schizophrenia have examined proinflammatory cytokines in the prenatal period and after schizophrenia onset, leaving the premorbid period unexamined. Understanding inflammation and immune abnormalities during the premorbid and prodromal periods of schizophrenia will play a crucial role in determining whether inflammation contributes to the neurodevelopmental course of schizophrenia. Currently, there are two primary theories with regard to how early immune insults might influence long-term immune functioning. There was no significant difference in allelic or genotypic distribution of the IL-1b gene polymorphisms (TaqI and 1B-175/1B-173) between schizophrenia patients and healthy control subjects Allelic and genotypic distributions of TaqI polymorphism in patients and control subjects were not significantly different
CI, confidence interval; FRET, fluorescence resonance energy transfer method; GSEA, Gene Set Enrichment Analysis; GWAS, genome-wide association study; HLA, human leukocyte antigen; ICCSS, Irish Case-Control Study of Schizophrenia; ISHDSF, Irish Study of High Density Schizophrenia Families; ITRIO, Irish Trio Study of Schizophrenia; MGS, Molecular Genetics of Schizophrenia; MHC, major histocompatibility complex; NES, normalized enrichments scores; NRG, neuregulin; OR, odds ratio; PAR, pseudoautosomal region; PCR, polymerase chain reaction; QC, quality control; RFLP, restriction fragment length polymorphism; SNP, single nucleotide polymorphism; SSCP, Single Strand Conformation Polymorphism; TDT, transmission disequilibrium test; TGF-b, transforming growth factor b; TNFR1, tumor necrosis factor receptor 1; WGA, whole-genome association; other abbreviations as in Table 1 .
a No effect size or odds ratio reported. b Effect size or odds ratio not reported in review. Calculated by authors on the basis of available data reported in manuscripts. One possibility is that fetal exposure to maternal infection and/or immune responses to infection create a focal lesion or brain pathology that is then reactivated in adolescence when normal developmental processes (e.g., synaptic pruning) occur (124) . Another possibility presumes greater developmental continuity, with fetal exposure to inflammation and/or infection leading to a cascade of neurodevelopmental sequelae that cumulatively result in long-term brain pathology and schizophrenia onset (64) . Along these lines, early alterations in immune function might lead to increased inflammation over time, which in turn can lead to brain abnormalities, such as those associated with schizophrenia. It is also possible that individuals exposed to maternal infection during pregnancy and/or inflammation might have subtle developmental difficulties that alter subsequent interactions with the environment across development. As mentioned in the preceding text, there is support for maternal infection during pregnancy leading to developmental problems in the premorbid period among children who later develop schizophrenia, such as cognitive and social problems (5, 26) . Similarly, maternal infection during pregnancy has been linked to developmental disorders, like autism, characterized by severe social and cognitive impairments (125) . However, what has not been tested is the possibility that premorbid difficulties interact with contextual factors (e.g., interactions with peers, family, teachers), which could subsequently create additional contextual stressors for the child (e.g., bullying from peers), which in turn could result in a cascade of difficulties for the child ultimately increasing risk for schizophrenia via numerous processes (e.g., increases in stress hormones). Contextual factors (e.g., peer influences and familial context) have largely been overlooked in studies of immune processes in schizophrenia, possibly due to difficulties measuring theses constructs nonetheless, contextual factors are important for future investigations to consider.
Finally, although genes associated with abnormal immune functioning have been linked to schizophrenia, it remains unclear whether genes and other individual-level factors (e.g., stress, diet, substance use) interact with pre-and postnatal immune insults such as infection and increased levels of proinflammatory cytokines to increase risk of schizophrenia and brain alterations associated with the disorder. Questions also remain with regard to the role of timing of immune insults. For example, the preponderance of ecologic data supports the association between second trimester infection and offspring schizophrenia, whereas more recent, methodologically rigorous studies have made it less clear which trimester or life period, if any, might be key in conferring risk for schizophrenia after infection/inflammation exposure (126) . With the exception of a few previously mentioned studies that have examined polymorphisms of the IL-3 and IL-10 genes, previous work on immune functioning in schizophrenia has predominantly examined T H 1-mediated immune responses, leaving the association between schizophrenia and T H 2 responses (127) in need of further examination, perhaps with dynamic measures of immune response-such as exposure to viruses (128)-to determine how T H 1 and T H 2 responses might work in tandem in schizophrenia.
Accumulating evidence has found relations between inflammation and immune function and risk of schizophrenia and schizophrenia-related brain alterations. In fact, there is preliminary evidence that treatments for infections and inflammation have promising results in schizophrenia populations. Specifically, herpes treatment in schizophrenia can improve cognition (19) and anti-inflammatory treatments can improve positive and negative symptoms in patients with schizophrenia (129) (130) (131) (132) ( Table 3) . Although some of these anti-inflammatory treatments have more severe side-effect profiles than others, antiinflammatory agents like omega-3 fatty acids have promising effects on the symptoms of schizophrenia and have very few known side effects (132) . Understanding how immune alterations operate within the course of the disorder is critical, especially given that inflammation and infection are fairly common in the population and represent potentially easy targets for early intervention and treatment.
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